Niranib 100mg Capsule (Niraparib)

Niranib 100mg Capsule is a prescription-based anticancer medicine used as maintenance treatment for advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The active ingredient of the Niranib is Niraparib, which belongs to the drug class of poly(ADP-ribose) polymerase (PARP) inhibitors. It works by blocking the action of PARP enzymes that repair damaged DNA in cancer cells. It prevents the cancer cells from repairing themselves, which leads to their cell death. This action can cause a decrease in cancer progression and cancer load.

The capsule must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the Niraparib 100mg capsule depend on the patient's condition and response to treatment. It can also be taken with or without food. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include nausea, fatigue, constipation, vomiting, abdominal discomfort, headache, dizziness, decreased appetite, and changes in blood cell counts. A few patients can undergo severe side effects, including severe anemia, low platelet or white blood cell counts, high blood pressure, heart-related complications, and rare but serious bone marrow disorders. Most of the Niraparib 100mg capsule side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

The medicine may cause fetal harm and should be used during pregnancy after the doctor advises. Women who can become pregnant should use effective contraception during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Niraparib 100mg capsule must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Head and neck cancer, kidney cancer, lung cancer, liver cancer, skin cancer

The human body shows undesired symptoms after taking Niranib 100mg Capsule (Niraparib). Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Some of the common side effects of Niranib Capsule are mentioned below:
● Nausea and vomiting
● Rash
● Diarrhea
● Dizziness
● Headache
● Muscle pain
● Stomach pain
● Constipation
● Bladder infection
● Decreased appetite
● High blood pressure
● Changes in your urine color
● Tiredness and trouble sleeping
● Lung problems, such as shortness of breath and cough
● Changes in blood levels including red blood cells, white blood cells, and platelets

Niranib 100mg Capsule (Niraparib) is a prescription-based anticancer drug that should be administered orally. Niranib is taken orally with or without food as per the doctor's advice.

It is consumed at the same time each day for better results. It is recommended not to crush, chew, or split the capsule, take it as a whole.

● Liu, M. C., Sutedja, J., & Tewari, K. S. (2021). Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy. Expert review of anticancer therapy, 21(5), 475-480.
● Kerliu, L., Myruski, S., Bhatti, A., Soni, P., Petrosius, P., Pervanas, H. C., & Horton, E. R. (2020). Niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Annals of Pharmacotherapy, 54(10), 1010-1015.
● González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., ... & Monk, B. J. (2019). Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 381(25), 2391-2402.
● Smith, M. R., Scher, H. I., Sandhu, S., Efstathiou, E., Lara, P. N., Yu, E. Y., ... & Moon, H. (2022). Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 23(3), 362-373.
● Ison, G., Howie, L. J., Amiri-Kordestani, L., Zhang, L., Tang, S., Sridhara, R., ... & Pazdur, R. (2018). FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clinical Cancer Research, 24(17), 4066-4071.
● Scott, L. J. (2017). Niraparib: first global approval. Drugs, 77(9), 1029-1034.